ATE532524T1 - Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs - Google Patents
Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebsInfo
- Publication number
- ATE532524T1 ATE532524T1 AT02731178T AT02731178T ATE532524T1 AT E532524 T1 ATE532524 T1 AT E532524T1 AT 02731178 T AT02731178 T AT 02731178T AT 02731178 T AT02731178 T AT 02731178T AT E532524 T1 ATE532524 T1 AT E532524T1
- Authority
- AT
- Austria
- Prior art keywords
- polysaccharide
- cancer
- treatment
- chemotherapeutic agent
- simultaneous administration
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000004676 glycans Chemical class 0.000 title abstract 2
- 229920001282 polysaccharide Polymers 0.000 title abstract 2
- 239000005017 polysaccharide Substances 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 abstract 1
- 229920000926 Galactomannan Polymers 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/818,596 US6645946B1 (en) | 2001-03-27 | 2001-03-27 | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US31709201P | 2001-09-04 | 2001-09-04 | |
| PCT/US2002/009524 WO2002076474A1 (en) | 2001-03-27 | 2002-03-27 | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE532524T1 true ATE532524T1 (de) | 2011-11-15 |
Family
ID=26980760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02731178T ATE532524T1 (de) | 2001-03-27 | 2002-03-27 | Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7012068B2 (de) |
| EP (1) | EP1383516B1 (de) |
| JP (1) | JP4744782B2 (de) |
| AT (1) | ATE532524T1 (de) |
| DK (1) | DK1383516T3 (de) |
| ES (1) | ES2376739T3 (de) |
| WO (1) | WO2002076474A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6680306B2 (en) | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| JP5021309B2 (ja) * | 2003-10-16 | 2012-09-05 | ステファン ジョン ラルフ | 免疫調節性組成物およびその使用方法 |
| WO2005056022A1 (ja) * | 2003-12-12 | 2005-06-23 | Taiyo Kagaku Co., Ltd. | 腸疾患改善用組成物 |
| CA2570570A1 (en) * | 2004-06-22 | 2006-01-05 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide |
| WO2006017417A2 (en) * | 2004-08-02 | 2006-02-16 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
| WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| WO2011016811A1 (en) * | 2009-08-07 | 2011-02-10 | Pro-Pharmaceuticals, Inc. | Methods for reducing the incidence of chemotherapy - induced mucositis |
| US8604187B2 (en) * | 2010-01-14 | 2013-12-10 | North Texas Medical Associates | Compositions and methods of aloe polysaccharides |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA3102155A1 (en) | 2018-06-29 | 2020-01-02 | Glykos Biomedical Oy | Conjugates |
| US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308838A (en) * | 1982-05-07 | 1994-05-03 | Carrington Laboratories, Inc. | Uses of aloe products |
| US5118673A (en) * | 1982-05-07 | 1992-06-02 | Carrington Laboratories, Inc. | Uses of aloe products |
| WO1993008810A1 (en) * | 1991-11-05 | 1993-05-13 | Carrington Laboratories, Inc. | Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure |
| JP3801658B2 (ja) | 1993-03-02 | 2006-07-26 | 太陽化学株式会社 | β−グルクロニダーゼ活性抑制組成物 |
| GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| EP0721784A4 (de) | 1994-07-29 | 1997-09-17 | Kanegafuchi Chemical Ind | Arzneimittelzubereitung mit kontrollierter freisetzung |
| US5861142A (en) * | 1996-03-25 | 1999-01-19 | Schick; Mary Pichler | Method for promoting hair, nail, and skin keratinization |
| AU7201998A (en) * | 1997-05-06 | 1998-11-27 | Zhi Liu | Drug delivery system |
| AU749623B2 (en) | 1998-03-26 | 2002-06-27 | Astellas Pharma Inc. | Sustained release preparations |
| KR20000011247A (ko) * | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
| WO2000018377A1 (en) | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| WO2000059481A1 (en) | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT |
-
2002
- 2002-03-27 ES ES02731178T patent/ES2376739T3/es not_active Expired - Lifetime
- 2002-03-27 WO PCT/US2002/009524 patent/WO2002076474A1/en not_active Ceased
- 2002-03-27 DK DK02731178.6T patent/DK1383516T3/da active
- 2002-03-27 EP EP02731178A patent/EP1383516B1/de not_active Expired - Lifetime
- 2002-03-27 US US10/108,237 patent/US7012068B2/en not_active Expired - Lifetime
- 2002-03-27 AT AT02731178T patent/ATE532524T1/de active
- 2002-03-27 JP JP2002574987A patent/JP4744782B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1383516A1 (de) | 2004-01-28 |
| EP1383516A4 (de) | 2007-08-01 |
| DK1383516T3 (da) | 2012-02-20 |
| US7012068B2 (en) | 2006-03-14 |
| US20030064957A1 (en) | 2003-04-03 |
| WO2002076474A1 (en) | 2002-10-03 |
| ES2376739T3 (es) | 2012-03-16 |
| JP4744782B2 (ja) | 2011-08-10 |
| EP1383516B1 (de) | 2011-11-09 |
| JP2004525143A (ja) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1383516A4 (de) | Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs | |
| ATE322265T1 (de) | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält | |
| GEP20053424B (en) | Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors | |
| ATE328599T1 (de) | Antitumorale mittel | |
| ATE307608T1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
| PT1420801E (pt) | Utilização de fucanos no tratamento de adesões, artrite e psoríase | |
| GEP20063805B (en) | Alkyne-Arylnaphthyridin-4-one as Phosphodiesterase-4 Inhibitors | |
| TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
| NO20054988D0 (no) | Preparater og metoder for behandling av cancer | |
| HUP0400231A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
| HUS1300069I1 (hu) | Dextrometorfánt és kinidint tartalmazó gyógyászati készítmények neurológiai rendellenességek kezelésére | |
| ATE441423T1 (de) | Verwendung von mastix und dessen ätherischen ílen zur verhinderung oder bekämpfung von mikrobieller infektionen | |
| ATE344670T1 (de) | Synergistische kombination zur behandlung von kolorektalkarzinom | |
| TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
| DE60036915D1 (de) | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln | |
| WO2005025501A3 (en) | Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
| EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
| DE60137069D1 (de) | Arzneizusammensetzungen enthaltend modafinilverbindungen | |
| FR2846327B1 (fr) | Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant. | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
| MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
| RU2002118825A (ru) | Бальнеологическое лечебно-профилактическое средство | |
| TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof |